Endocrine Abstracts

Research question: What are the differences in foetal size in early pregnancy between GDM and control.Methods: Serial foetal biometry was performed for GDM women and controls at 18–20 weeks and 28–32 weeks. At each visit, abdominal and head circumference (AC) & (HC), femur length (FL) and abdominal wall thickness (AWT) was measured along with collection of maternal data.Results: women with GDM and 184 controls had com...

Research question: Are there ethnic differences in foetal growth patterns in GDM?Methods: Retrospective data collection was undertaken for all women with GDM between 2008 and 2012 at University Hospital Coventry. Foetal biometric data was obtained at 28, 32, and 36 weeks gestation for 125 South-Asian (SA) and 142 WC.Results: Compared to WC, SA had had lower BMI (28.5±6.1 kg/m2 vs 32.2±7.4 kg/m2), hei...

A 64-year-old female presented to the acute medical take with hypercalcaemia. She had a 3 weeks history of polyuria, polydipsia, constipation, intermittent abdominal pain and feeling depressed. She reported weight loss of 3.5 kg over the past 6 months. She denied symptoms of dysphagia, dyspnoea, haemoptysis, haematemesis, or malaena. Her past medical history included anaemia, ischaemic heart disease, chronic obstructive pulmonary disease and uterine prolapse. She was an ex-smo...

Aim: Over the last decade, cardiac valvular fibrosis has been associated with the use of high dose (ergot-derived) dopamine agonist therapy in Parkinson’s disease. Although the risk in endocrine patients appears significantly lower, routine echocardiographic monitoring is now recommended. This study evaluated the incidence of significant cardiac valvulopathy in endocrine patients treated with cabergoline in a District General Hospital Population, and compliance with MHRA ...

Thyroid eye disease (TED) is clinically evident in 25–50% of patients with Graves’ disease and 3–5% of cases develop severe eye disease. We present a case of very aggressive TED.A 46-year-old gentleman developed graves thyrotoxicosis and was blocked and replaced with carbimazole and thyroxine. He continued to smoke 20 cigarettes/day despite several advises.He developed marked exophthalmos (L>R), chemosis, with re...

Background: Patients with neuroendocrine tumors (NETs) have divergent survival, even when having the same site of primary tumor, and tumor stage and grade. 68Gallium (68Ga)-DOTATATE positron emission tomography (PET)/computed tomography (CT) is a sensitive imaging modality for detecting NETs. The purpose of this study was to determine whether 68Ga-DOTATATE PET/CT imaging has any prognostic utility in patients with NETs.Methods: One hundred and eighty-fou...

Purpose: To examine two cases of teenagers after transnasal removal of pituitary volume of education followed by recombinant growth hormone therapy Dzhintropinom (Eurofarm).Materials and methods: During the period of 2014 in the department of paediatric endocrinology and neuroendocrinology RSNPM Endocrinology Center MoH (Tashkent), we examined two male patients, including the patient F., 2.5 g of a craniopharyngioma, and the second patient For 15 years w...

Introduction and objective: Cardiovascular mortality is high in acromegaly. Our aim in this study was to determine the levels of the new cardiovascular marker in active acromegaly patients, the mean platelet volume (MPV) values before and after octreotide acetate long-acting repeatable treatment.Material and methods: Thirty-six patients with active acromegaly who presented at the Endocrinology Department (mean age 46.0±14.0 years and mean BMI: 30.4&...

Aim: Isolated male hypogonadotropic hypogonadism can be congenital or acquired. Mean platelet volume (MPV), which is a determinant of platelet function, is an independent risk factor for cardiovascular disease. The aim of this study is to evaluate MPV values in untreated, normosmic, isolated, male, idiopatic hypogonadotropic hypogonadism (IHH) patients, and the relationships among MPV, low testosterone levels, metabolic syndrome, impaired fasting glucose (IFG) and cardiovascul...

Introduction: Generously supported by IPSEN)-->Surgery is recognized first-line therapy for acromegalic patients but tumour size and GH/IGF1 control has also been observed after primary somatostatin analogue treatment. This is the first study of therapy with high-dose lanreotide Autogel over one year in a large cohort of treatment-naïve acromegalic patients.Methods: In this international, multicentre, open...